AZD3759 Low Form

AZD3759 Low FormAZD3759 is a potent, oral active, CNS penetrant EGFR inhibitor with IC50 of 0. 3 nM, 0. 2 nM, and 0. 2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.

Repaglinide is a potassium channel blocker

which blocks shedding of cytokine receptors

15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR

33mm HDPE cap with 18in Female Luer and Male Luer Lock Plug

31760-500C)

aliphatic amino acid that is used in the biosynthesis of proteins

NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0

Approximate dish cover diameter and height is 150x20mm

tiopropium) that is an anticholinergic and bronchodilator and a muscarinic receptor antagonist

with putative activity against several bacteria

Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity

Betulinic acid